Eris Lifesciences Limited — Others, 21-02-2025: Redemption

Eris Lifesciences Limited has announced a board meeting to discuss the redemption of 43,750 8% Secured Unlisted Redeemable Non-Convertible Debentures, amounting to ₹437.50 crore. This step fulfills an obligation linked to the acquisition of Swiss Parenteral Limited, with the NCDs issued as part of the purchase price. The redemption aligns with previously established terms and does not impact the company's overall debt position. This move may reflect positively on investor sentiment by demonstrating financial discipline and adherence to commitments, while maintaining the current leverage profile.